NO951762L - Stabilt preparat for behandling av blodkoagulasjonssykdommer, omfattende et aktivt koagulasjonsfremmende stoff - Google Patents

Stabilt preparat for behandling av blodkoagulasjonssykdommer, omfattende et aktivt koagulasjonsfremmende stoff

Info

Publication number
NO951762L
NO951762L NO951762A NO951762A NO951762L NO 951762 L NO951762 L NO 951762L NO 951762 A NO951762 A NO 951762A NO 951762 A NO951762 A NO 951762A NO 951762 L NO951762 L NO 951762L
Authority
NO
Norway
Prior art keywords
treatment
blood coagulation
coagulation
active
disorders
Prior art date
Application number
NO951762A
Other languages
English (en)
Norwegian (no)
Other versions
NO951762D0 (no
Inventor
Johann Eibl
Hans Peter Schwarz
Jurgen Siekmann
Peter Turecek
Original Assignee
Immuno Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immuno Ag filed Critical Immuno Ag
Publication of NO951762D0 publication Critical patent/NO951762D0/no
Publication of NO951762L publication Critical patent/NO951762L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4866—Protein C (3.4.21.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/647—Blood coagulation factors not provided for in a preceding group or according to more than one of the proceeding groups
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21006—Coagulation factor Xa (3.4.21.6)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21021—Coagulation factor VIIa (3.4.21.21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21069—Protein C activated (3.4.21.69)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dispersion Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
NO951762A 1994-05-06 1995-05-05 Stabilt preparat for behandling av blodkoagulasjonssykdommer, omfattende et aktivt koagulasjonsfremmende stoff NO951762L (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE4416180A DE4416180C2 (de) 1994-05-06 1994-05-06 Stabiles Präparat zur Behandlung von Blutgerinnungsstörungen und Verfahren zur Herstellung dieses Präparats

Publications (2)

Publication Number Publication Date
NO951762D0 NO951762D0 (no) 1995-05-05
NO951762L true NO951762L (no) 1995-11-07

Family

ID=6517576

Family Applications (1)

Application Number Title Priority Date Filing Date
NO951762A NO951762L (no) 1994-05-06 1995-05-05 Stabilt preparat for behandling av blodkoagulasjonssykdommer, omfattende et aktivt koagulasjonsfremmende stoff

Country Status (7)

Country Link
EP (1) EP0680763A3 (sv)
JP (1) JPH0840928A (sv)
AT (1) ATA77095A (sv)
CA (1) CA2148672A1 (sv)
DE (1) DE4416180C2 (sv)
FI (1) FI952170A (sv)
NO (1) NO951762L (sv)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4416166C2 (de) * 1994-05-06 1997-11-20 Immuno Ag Stabiles Präparat zur Behandlung von Blutgerinnungsstörungen
EP0796623B1 (de) * 1996-03-20 2005-05-25 Baxter Aktiengesellschaft Pharmazeutisches Präparat zur Behandlung von Blutgerinnungsstörungen
AU4709399A (en) * 1998-06-23 2000-01-10 Victor J. Marder Phospholipid vesicle-tissue factor complex preparations and methods of making and using same
US7056529B2 (en) * 2002-05-14 2006-06-06 University Of Louisville Research Foundation, Inc. Direct cellular energy delivery system
CA2660310C (en) 2006-03-30 2015-04-21 The Research Foundation Of State University Of New York Compositions of less immunogenic and long-circulating protein-lipid complexes
EP3253870B1 (en) 2015-02-06 2021-06-23 Guangzhou Bioseal Biotech Co., Ltd. Method for preparation of thrombin
WO2020080496A1 (ja) * 2018-10-17 2020-04-23 東レ株式会社 止血材

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4348384A (en) * 1980-10-17 1982-09-07 Dainippon Pharmaceutical Co., Ltd. Pharmaceutical composition for oral administration containing coagulation factor VIII or IX
JPS5770814A (en) * 1980-10-17 1982-05-01 Isamu Horikoshi Oral preparation of blood clotting eighth factor
GB2129685B (en) * 1982-11-11 1985-11-13 Nat Biolog Standards Board Anti-haemophilic compositions
US4721618A (en) * 1983-06-27 1988-01-26 Queen's University At Kingston Method for controlling bleeding
US4610880A (en) * 1983-06-27 1986-09-09 Queen's University At Kingston Composition for controlling hemophilia in mammals
AT389815B (de) * 1984-03-09 1990-02-12 Immuno Ag Verfahren zur inaktivierung von vermehrungsfaehigen filtrierbaren krankheitserregern in blutprodukten
WO1990003808A1 (en) * 1988-10-07 1990-04-19 The Liposome Company, Inc. Heat treating liposomes
WO1991002532A2 (en) * 1989-08-14 1991-03-07 Queen's University At Kingston Method for stimulating fibrinolytic effect
US5504064A (en) * 1991-04-10 1996-04-02 Oklahoma Medical Research Foundation Treatment of bleeding with modified tissue factor in combination with an activator of FVII
AU7384994A (en) * 1993-08-06 1995-02-28 Opperbas Holding B.V. A method for high loading of vesicles with biopolymeric substances
DE4416166C2 (de) * 1994-05-06 1997-11-20 Immuno Ag Stabiles Präparat zur Behandlung von Blutgerinnungsstörungen

Also Published As

Publication number Publication date
FI952170A0 (sv) 1995-05-05
ATA77095A (de) 2002-04-15
JPH0840928A (ja) 1996-02-13
NO951762D0 (no) 1995-05-05
CA2148672A1 (en) 1995-11-07
EP0680763A3 (en) 1998-01-28
DE4416180A1 (de) 1995-11-09
DE4416180C2 (de) 1997-08-14
FI952170A (sv) 1995-11-07
EP0680763A2 (en) 1995-11-08

Similar Documents

Publication Publication Date Title
NO951761L (no) Stabilt preparat for behandling av blodkoagulasjonssykdommer
BR0206985A (pt) Anticorpos modificados e métodos de uso
DE69530763D1 (de) Antikörper gegen e-selektin
BR0007840A (pt) Proteìnas de fusão her-2/neu
GEP19981289B (en) Method for Preparing Preserved Medicinal Means Containing Human Protein and Medicinal Means
NO166943C (no) Analogifremgangsmaate for fremstilling av enzymresistente immunomodulerende peptider.
HUP0105090A2 (hu) Kóros elhízás elleni fehérjék expressziója és exportja Fc fúziós fehérje formájában
PT758248E (pt) Formulacoes para o factor ix
HUP0300868A2 (hu) Ellenanyag-citokin fúzíós fehérje által közvetített immunválaszok fokozása immuncitokin felvételét elősegítő anyagokkal történő kombinált kezeléssel
ATE198050T1 (de) Therapeutische anwendungen von bpi-protein- produkten zur behandlung von humaner meningococcämia
DK0865294T3 (da) Fremgangsmåder til reduktion eller bibeholdelse af reducerede niveauer afblodlipider under anvendelse af OB-proteinpræparater
MX9603925A (es) Combinaciones de anticoagulantes y proteinas activas tromboliticamente, y usos de las mismas.
DE69726759D1 (de) Cytopatische viren zur therapie und prophylaxe der neoplasie
EP0797999A3 (en) Formulations of obesity protein
ATE234111T1 (de) Therapeutische verwendungen von bpi-protein produkten bei menschen mit durch trauma verursachter blutung
Avanoglu et al. Safer circumcision in patients with haemophilia: the use of fibrin glue for local haemostasis
PH12019502522A1 (en) Oncolytic virus and method
NO951762L (no) Stabilt preparat for behandling av blodkoagulasjonssykdommer, omfattende et aktivt koagulasjonsfremmende stoff
Nilsson et al. The Use of Human Anti-haemophiiic Globulin (Fraction IO) in Haemophilia A and in von Willebrand’s Disease
DE3584775D1 (de) Zusammensetzung zur behandlung von an haemophilia-a-inhibitor leidenden kranken.
HUP9900506A2 (hu) Protrombinszármazékok
DK1165102T3 (da) Matrixproteinpræparater til podning i ikke-mineraliseret væv
BRPI0416461A (pt) método para o tratamento de episódios de sangramento, formulação farmacêutica, e, uso de um polipeptìdeo fxi
Kido et al. A simple method for purification of chymase from rat tongue and rat peritoneal cells
WO1996020950A3 (en) Compositions and methods for treating rheumatoid arthritis